Compare DuPont de Nemours Inc (DD) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs 22nd Century Group Inc — how do they compare? DuPont de Nemours Inc trades at $130.47 (market cap $17.89B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: DuPont de Nemours Inc is far larger — about 28777.3× 22nd Century Group Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and 22nd Century Group Inc for 32 Days on average.
| DD | XXII | |
|---|---|---|
Market Cap | $17.89B | $621.67K |
Volume | 816,409 | 45,625 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $154.59 | $483.00 |
52-Week Low | $92.49 | $0.80 |
Typical Hold Time | 89 Days | 32 Days |
Enterprise Value | $19.28B | -$3.69M |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with a neutral technical signal and mixed fundamentals. Recent earnings have consistently beaten estimates, but 2025 saw a net loss of $779 million on revenue of $6.85 billion. The company maintains innovation with new product launches like the Sugar Separation Advisor and Tyvek with Renewable Attribution, while facing headwinds from legal settlements and uneven demand.
The outlook is cautious; analyst consensus is bullish with a 58.54% buy rating but a price target of $95.00 below the current price. Key opportunities include margin expansion in growth markets, while risks involve PFAS litigation costs, volatile cash flows, and execution challenges in a competitive landscape.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
